Graft-versus-host disease and relapse/rejection-free survival after allogeneic transplantation for idiopathic severe aplastic anemia: a comprehensive analysis from the SAAWP of the EBMT

Survival after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for severe idiopathic aplastic anemia (SAA) has improved in recent years, approaching 75% at 5 years. However, an SAA-adapted composite endpoint, graft-versus-host disease (GvHD) and relapse/rejection-free survival (GRFS),...

Descripción completa

Detalles Bibliográficos
Autores principales: Devillier, Raynier, Eikema, Dirk-Jan, Dufour, Carlo, Aljurf, Mahmoud, Wu, Depei, Maschan, Alexei, Kulagin, Alexander, Halkes, Constantijn J. M., Collin, Matthew, Snowden, John, Renard, Cécile, Ganser, Arnold, Sykora, Karl-Walter, Gibson, Brenda E., Maertens, Johan, Itäla-Remes, Maija, Corti, Paola, Cornelissen, Jan, Bornhäuser, Martin, Araujo, Mercedes Colorado, Ozdogu, Hakan, Risitano, Antonio, Socie, Gerard, de Latour, Regis Peffault
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2023
Materias:
Article - Aplastic Anemia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483355/
https://www.ncbi.nlm.nih.gov/pubmed/36951165
http://dx.doi.org/10.3324/haematol.2022.281876

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483355/
https://www.ncbi.nlm.nih.gov/pubmed/36951165
http://dx.doi.org/10.3324/haematol.2022.281876

Ejemplares similares